BioCorteX
Company Overview
BioCorteX is a pioneering biotechnology enterprise with offices in _London, New York, and Adelaide_. Founded in 2021, BioCorteX is widely recognized for its leadership in developing computational simulations and knowledge-driven platforms aimed at decoding the complex interactions among bacteria, the human immune system, diseases, and pharmaceutical interventions.
Core Innovations and Competencies
BioCorteX's unique technological advancements include Carbon Knowledge™ and Carbon Mirror™. These platforms employ a vast knowledge graph composed of millions of microbiome samples from over 165 geopolitical regions, covering diverse microbiomes such as human, animal, soil, and water. A central aspect of their technology focuses on refining and de-risking clinical trials spanning pharmaceuticals, cosmetics, and manufacturing sectors, with particular emphasis on drug-bacteria interactions and their physiological and tissue-specific effects.
Carbon Mirror™, essential to BioCorteX's breakthroughs, emulates foundational biology using their extensive knowledge graph, Carbon Knowledge™. This approach provides significant insights into microbiomes' interplay with human physiology and drugs, facilitating next-generation therapeutic developments that cater to individual and population diverse needs, moving beyond the traditional 'one-size-fits-all' model.
Strategic Partnerships and Developments
BioCorteX's strategic venture, in collaboration with _Google Cloud_, targets Antibody-Drug Conjugate (ADC) cancer treatments. This partnership focuses on the impact of drug-bacteria dynamics in tumor environments, leveraging _Google Cloud's_ prowess in data analytics to develop personalized medicine solutions.
Funding and Investment
The company, while privately held, has successfully secured $5 million in a 2023 funding round led by _Sofinnova Partners_ and _Hoxton Ventures_. This capital aims to boost research capacity in drug-bacteria interactions, with company valuations estimated between _US $20–30 million_ as of early 2023.
Leadership and Board
- Nik Sharma: CEO & Co-Founder. Based in the _Greater Cambridge Area_, Sharma brings expertise in neurology, data, and machine learning, driving BioCorteX's mission to redefine drug development.
- Muhannad Alomari: CTO & Co-Founder. A graduate from the _University of Leeds_ and located in the _UK_, Alomari propels advancements in biotechnology and cancer treatments, playing vital roles in partnerships with tech giants like _Google Cloud_.
Board Members
- Jackie Hunter, PhD DSc CBE FBPharmacolS FMedSci FZSL: Chair of the Board, brings extensive experience in pharmaceutical research.
- Edward Kliphuis: Partner at _Sofinnova Partners_.
- Hussein Kanji: Partner at _Hoxton Ventures_.
Contact Information
- Website: [BioCorteX Official Website](https://biocortex.com/)
- Email: [info@biocortex.com](mailto:info@biocortex.com)
- Headquarters: _167-169 Great Portland Street, London_
- Social Media: [BioCorteX Twitter](https://x.com/bio_cortex)
Competitive Landscape
BioCorteX operates in a competitive biotechnology sphere, specifically in drug development for neurodegenerative diseases, using its unique microbiome platforms. Key competitors include:
- Biogen: Significant for treating neurological conditions, well-established since 1978.
- Denali Therapeutics: Focus has been on neurodegenerative diseases, aiming for breakthroughs in therapies like Alzheimer's.
- Nanomerics: Competes in precision medicine with its cutting-edge Molecular Envelope Technology.
- Quell Therapeutics: Provides cellular therapies addressing therapeutic needs, enhancing drug development competition.
Operating Environment
BioCorteX, with a team of 11–50 employees, maintains an agile ecosystem in London, strategically positioned amidst a rich R&D environment. The company remains focused on technological agility and rapid development to solidify its market stance.
